664. Are Thousands of Medical Cures Hiding in Plain Sight?

664. 数千种医疗疗法是否就隐藏在我们眼前?

Freakonomics Radio

2026-02-20

51 分钟
PDF

单集简介 ...

Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.   SOURCES: Chris Snyder, professor of economics at Dartmouth College. David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania. Heather Stone, health science policy analyst at the Food & Drug Administration. Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.   RESOURCES: Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019). Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016). Market Shaping Accelerator. CURE ID Registry. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
更多

单集文稿 ...

  • The trade on the financial markets can be a unique opportunity.

  • If you want to know how to activate the dark mode on your platform or how you can pay for your account,

  • then it's good to talk to a real person.

  • At capital.com, our teams speak German, French, Italian, Spanish and many other languages.

  • Join us and we would like to help you answer your questions on the topic of trading.

  • capital.com Discover a broker who speaks your language.

  • CFDs are highly risky.

  • 86% of the investors There is a horrible infectious disease that you have probably never heard of.

  • It's called balymuthia.

  • It's basically your brain eating amoeba.

  • They don't really know how it's transmitted, probably through some sort of soil exposure.

  • It causes encephalitis, which is swelling in parts of the brain.

  • It can kill you in relatively short order.

  • It's extremely rare, and so there's been very little study of it.

  • That is Heather Stone.

  • She is a health science policy analyst in the Food and Drug Administration.

  • The FDA has not approved any treatments for balymuthia,

  • but that doesn't necessarily mean there aren't any treatments.

  • Three or four years ago,

  • a clinician in San Francisco at University of California treated the first patient with a drug called nitroxylene,